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Abstract  
Background: Recognition that ascending infection leads to preterm birth has led to a number 
of studies that have evaluated the treatment of vaginal infections in pregnancy to reduce 
preterm birth rates.  However, the role of candidiasis is relatively unexplored. Our aim was to 
undertake a systematic review and meta-analysis to assess whether treatment of pregnant 
women with vulvovaginal candidiasis reduces preterm birth rates and other adverse birth 
outcomes. 
Methods: We undertook a systematic review and meta-analysis of randomised controlled 
trials (RCTs) in which pregnant women were treated for vulvovaginal candidias (compared to 
placebo or no treatment) and where preterm birth was reported as an outcome. Trials were 
identified by searching the Cochrane Central Register of Controlled Trials, Medline and 
Embase databases to January 2014. Trial eligibility and outcomes were pre-specified. Two 
reviewers independently assessed the studies against the agreed criteria and extracted relevant 
data using a standard data extraction form. Meta-analysis was used to calculate pooled rate 
ratios (RR) and 95% confidence intervals (CI) using a fixed-effects model.  
Results: There were 2 eligible RCTs both among women with asymptomatic candidiasis, 
with a total of 685 women randomised. Both trials compared treatment with usual care (no 
screening for, or treatment of, asymptomatic candidiasis). Data from one trial involved a 
post-hoc analysis of a larger trial of treatment of asymptomatic infections in pregnancy 
(n=586) and the other was a pilot study (n=99). There was a significant reduction in 
spontaneous preterm births in treated compared with untreated women (meta-analysis 
RR=0.36, 95%CI 0.17-0.75). No other outcomes were assessed by both trials. 
Conclusions: This systematic review found two trials comparing treatment of vaginal 
candidiasis in pregnancy for the outcome of preterm birth. Although the effect estimate 
provides support for the hypothesis that treatment of asymptomatic candidiasis may reduce 
3 
 
the risk of preterm birth, the result needs to be interpreted with caution as the primary driver 
for the pooled estimate comes from a post-hoc analysis. A prospective trial with sufficient 
power to answer the clinical question ‘does treatment of asymptomatic candidiasis in early 
pregnancy prevent preterm birth’ is warranted. 
 
Systematic review registration: PROSPERO CRD42014009241 
 
Keywords: pregnancy, preterm birth, premature infant, candida, candidiasis, yeasts, 
randomized controlled trial, met-analysis 
4 
 
Background  
Preterm birth is a major pregnancy complication affecting 5-18% of births worldwide.[1, 2] 
Infants born preterm are at increased risk of death, significant neonatal complications, long-
term adverse health outcomes and developmental impairment.[3-5] 
 
Preterm birth (birth before 37 completed weeks’ of gestation) results from either spontaneous 
onset of labour (including preterm prelabour rupture of the membranes) or a clinical decision 
that planned birth should occur because of pregnancy complications. The cause of 
spontaneous preterm birth is often unknown, but intrauterine infection is implicated in up to 
40%.[4, 6, 7] The likely pathway to intrauterine infection is ascending genital tract 
infection.[6-9] Genital tract infection is more frequent among women with spontaneous 
preterm births at lower gestational ages.[7, 10] Importantly infection may occur before or 
early in pregnancy, may be asymptomatic and may remain undetected.[7, 11] 
 
The role of infection in preterm birth is thought to be a chronic process, with early pregnancy 
a period of vulnerability to establishment of inflammatory responses that may be the trigger 
for preterm parturition.[6, 9, 11] Organisms detected in the uterus before membrane rupture 
are typically of low virulence, probably accounting for both the chronicity of intrauterine 
infections and the frequent absence of overt clinical signs of infection.[6, 8] 
 
Pregnancy increases the frequency of vaginal Candida colonization.[12] This is thought to be 
the consequence of increased levels of circulating oestrogens and deposition of glycogen and 
other substrates in the vagina during pregnancy.[12] Candida colonisation may disrupt 
normal vaginal flora so that there is a decrease in lactobacilli and an increase in 
proinflammatory organisms.[9, 13] However few studies have assessed associations between 
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candidiasis and preterm birth. Studies utilising population-based data from Hungary found 
that vaginal clotrimazole treatment of candidiasis during pregnancy was associated with a 34-
64% reduction in the prevalence of preterm birth.[14-16]  In contrast, two cohort studies 
found no significant association between preterm birth and moderate to heavy growth of 
Candida species among women at 22-30 weeks gestation.[17, 18] Therefore, our aim was to 
undertake a systematic review and meta-analysis to assess whether treatment of pregnant 
women with vulvovaginal candidiasis reduces preterm birth rates and other adverse birth 
outcomes.  
 
Methods 
The study procedure and outcomes were pre-specified.[19] We identified relevant studies by 
searching the Cochrane Central Register of Controlled Trials, Medline and Embase from data 
base inception through 31 January 2014. There were no language restrictions. The database 
searches were supplemented by hand-searching reference lists of relevant publications. 
Search terms (all exploded) included (“candida” or “candidiasis” or “candidosis” or “yeasts”) 
and (“pregnancy” or “preterm/premature birth”) and “antifungal agents”. Abstracts were not 
included and no attempt was made to identify unpublished studies. 
 
Randomised controlled trials (RCT) in which pregnant women were treated for vulvovaginal 
candidiasis and where preterm birth was reported as an outcome were the prespecified 
eligibility criteria.[19]  Only RCTs that compared treatment (imidazoles or other proven 
therapeutic agents) with placebo or no intervention could answer the research question. 
Quasi-randomised designs, such as alternate allocation or use of medical record numbers, 
were not eligible.  Studies of pregnant women with vulvovaginal candidiasis (symptomatic or 
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asymptomatic) were eligible for inclusion. Mycologically confirmed diagnoses of 
vulvovaginal candidiasis (ie a positive culture and/or microscopy for yeast) were required. 
The titles and abstracts of all potential studies identified for inclusion as a result of the search 
strategy were independently assessed for inclusion by two reviewers. Two reviewers also 
assessed the full papers of potentially eligible studies or where eligibility was unclear. 
Discrepancies were resolved through discussion. 
 
Two review authors also independently assessed the risk of bias (as low, high or unclear) for 
each study using the following pre-specified criteria: random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, and 
completeness of outcome data.[19] 
 
Preterm birth (<37 completed weeks of gestation) following spontaneous onset of labour 
and/or preterm prelabour rupture of membranes was the primary outcome. Secondary infant 
outcomes included: any birth before 37 weeks, medically indicated birth (by labour induction 
or prelabour caesarean section) before <37 weeks, birth before 32 weeks, birthweight less 
than the tenth percentile for gestational age, birthweight <2500 grams, Apgar score of less 
than seven at five minutes, respiratory distress syndrome, use of mechanical ventilation, 
duration of mechanical ventilation, intraventricular haemorrhage, retinopathy of prematurity, 
chronic lung disease, necrotising enterocolitis, neonatal sepsis, perinatal mortality (stillbirth 
or neonatal death), admission to neonatal intensive care unit, neonatal length of hospital stay 
and breastfeeding. Secondary maternal outcomes included: preterm prelabour rupture of the 
membranes, spontaneous pregnancy loss <20 weeks gestation, mode of birth, duration of 
maternal hospitalisation at the time of birth, treatment side effects, maternal 
views/satisfaction with the therapy and maternal anxiety. 
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We also prespecified two subgroup analyses for the primary outcome: symptomatic and 
asymptomatic candidiasis, and commencing treatment before 20 weeks’ gestation versus after 
20 weeks’ gestation. 
 
Data were independently extracted from each paper by two reviewers onto a standard data 
extraction form. Statistical analyses were performed using the ‘metan’ command in STATA. 
(STATA statistical software version 11.0, STATA, College Station, USA). Where data were 
missing (incomplete follow up on all women), the results reported in the studies as the 
numerator and denominator were used. For each dichotomous outcome of interest within 
individual studies, relative risks (RR) and 95% confidence intervals (CIs) were calculated 
according to the intention to treat. For continuous variables, the weighted mean differences 
and 95% CIs were calculated (with a log transformation for mean length of stay). The 
assumption of homogeneity of treatment effect between studies would use Cochran’s Q test 
statistic and the I
2
 test, if more than two trials were identified. Overall estimates of effect 
utilised a fixed effect model (Mantel–Haenszel), unless the assumption of homogeneity was 
rejected (P < 0.1) when a random effects model would be used. 
 
Results 
A total of 1014 unique articles were identified (Figure 1). Of these 17 underwent full review 
as potentially eligible or where the eligibility was unclear from the title and abstract.[20-36] 
There were no potentially eligible studies that utilised quasi-randomised designs. Only 3 
papers compared treatment versus placebo or no intervention for pregnancy women with 
candidiasis.[28, 34, 36] One of these trials compared treatment with placebo for women with 
confirmed (clinically and mycologically) vaginal candidiasis at 32-36 weeks gestation.[36] 
However, the only outcomes reported in this trial were maternal and infant Candida 
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colonisation at the time of birth, no birth outcomes. Furthermore, the gestation at enrolment 
was not consistent with preventing preterm birth. The remaining two studies included 
asymptomatic women with vaginal candidiasis and both compared treatment with 
clotrimazole to no treatment (Table 1).[28, 34] Preterm birth was the primary outcome for 
both studies. 
 
The aim of the study by Kiss and colleagues was to assess whether general screening for, and 
treatment of, asymptomatic vaginal infections (bacterial vaginosis, candidiasis and/or 
trichomoniasis) was effective in reducing the rate of preterm birth and late miscarriage.[28] 
Women who were culture positive for any of the 3 conditions (N=4429) were randomised to 
treatment (appropriate to the organism: clindamycin, clotrimazole and/or metronidazole 
respectively) or to usual care (culture result not revealed and no treatment). The information 
on treatment of asymptomatic candidiasis from this trial was obtained post-hoc from the 
published paper.  Overall, the preterm birth rate in this trial was reduced from 5.3% to 3.0% 
(P<0.001).  
 
Drawing on the post-hoc findings by Kiss et al, Roberts and colleagues undertook a pilot 
study with the specific aim of assessing treatment of asymptomatic candidiasis to prevent 
preterm birth.[34] The study design was essentially the same although the eligibility criteria 
were limited to women with asymptomatic candidiasis. 
 
Both studies utilised computer random number generation and central randomisation 
procedures. In the Kiss et al study, women who were randomised to treatment (and their 
obstetricians) were not blinded to the treatment allocation. However the untreated group 
(93% of women screened) included both women without infections, and those with 
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asymptomatic infections who were randomised to usual care.  Clinicians and women were 
blinded to the colonisation-status within this group. Roberts et al used a similar method but 
women allocated to treatment were notified and treated by the study personnel. So although 
the treated women were not blinded, clinicians were blinded to treatment allocation unless it 
was revealed during the subsequent pregnancy management.  Like the Kiss et al study, the 
untreated group (90% of participants) included women with and without asymptomatic 
candidiasis and the clinicians and women were blinded to this information. This partial 
blinding of participants and personnel was considered unlikely to affect results. Furthermore 
the assessment of outcomes from medical records was blinded. Because the analysis of 
candidiasis in the Kiss et al study was post-hoc, loss to follow-up by treatment group for 
women with candidiasis cannot be assessed. However overall 3.2% women were lost to 
follow-up and there were 3.0% post-randomisation exclusions (1.5% multiple pregnancies; 
1.5% did not fulfil the inclusion criteria). The follow-up rate was 99% in the Roberts et al 
study with no post-randomisation exclusions. 
 
For both studies, the risk of bias was considered low for all aspects assessed: random 
sequence generation, allocation concealment, blinding of participants and personnel, blinding 
of outcome assessment, and completeness of outcome data. 
 
The asymptomatic Candida colonisation rate was 14.1% (15-19 weeks gestation) in the Kiss 
et al study and 19.6% (12-19
 
weeks gestation) in the Roberts et al study.  Kiss et al reports 
women were to be retested, and if necessary retreated, at 24 to 27 weeks. However overall 
only 22% of women in the entire treatment arm had a follow-up gram stain and of these 27% 
still had a vaginal infection present, including 78 (27%) with candidiasis, all of whom were 
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retreated. Roberts et al report a post-treatment colonisation rate of 48% on average 10 weeks 
after recruitment but women were not offered further treatment. 
 
The only outcome available from both studies was spontaneous preterm birth.  Among the 
586 women with candidiasis in the Kiss study, treatment was associated with a reduction in 
spontaneous preterm births from 22 (7.5%) in the usual care group to 8 (2.7%) in the 
clotrimazole. Roberts et al reported comparable preterm birth rates (3 (6%) and 1 (2%) 
respectively, but with very small numbers.  Meta-analysis showed an overall reduction in 
preterm birth (RR 0.36, 95% CI 0.17, 0.75) with similar point estimates from both studies but 
little contribution (and very wide confidence intervals) around the estimate from the pilot 
study by Roberts et al. (Figure 1). 
 
Roberts et al also reported no differences between the treated and untreated groups of women 
for any preterm birth, pregnancy complications, mode of delivery and birth weight but 
interpretation is again limited by the small numbers.  
 
Discussion 
This systematic review found two trials comparing treatment of asymptomatic vaginal 
candidiasis in pregnancy with usual care (no screening and no treatment of asymptomatic 
vaginal candidiasis) for the outcome of preterm birth. The similarity of the individual trial 
effect estimates provides support for the hypothesis that treatment of asymptomatic 
candidiasis may reduce the risk of preterm birth in most maternal populations. However, 
although the two studies had similar methods, treatment regimens and findings among 
different populations, the result needs to be interpreted with caution as the primary driver for 
the pooled estimate is a post-hoc analysis of the Kiss trial.  We believe the meta-analysis 
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result supports the need for a larger trial that specifically addresses the question of whether 
treatment of asymptomatic candidiasis early in pregnancy can reduce the risk of spontaneous 
preterm birth. 
 
The two trials reported different colonisation rates of asymptomatic candidiasis (14.1% and 
19.6%).[28, 34] This reflects different population baseline characteristics and slightly varying 
gestational age ranges for recruitment. Other studies report colonisation rates that range from 
14% to 38% for symptomatic candidiasis at 22-30 weeks gestation but do not report 
asymptomatic rates.[17, 18, 37] Some of the population risk factors for candidiasis are also 
risk factors for preterm birth including African-American women, low socio-economic status, 
smoking, maternal medical conditions, and bacterial vaginosis.[15, 17, 28]  
 
Both trials included in the meta-analysis used a similar design, described by Roberts et al as a 
Prospective, Randomised, Open-label, Blinded-Endpoint (PROBE) design.  PROBE designs 
have been used in cardiovascular disease trials,[38-45] and the two trials in this review may 
be the first obstetric trials to use this design. Features include strict randomisation and 
allocation concealment procedures, and blinding of those assessing the trial endpoints.[40] 
The drug interventions are typically commercially available as indicated in the Roberts 
trial.[34] Consequently, as the treatment protocol adheres closely to routine clinical practice, 
the results from a PROBE design may be more generalisable to the pragmatic management of 
patients than double-blind, placebo-controlled trials.[40, 44]  Roberts et al suggest two other 
potential disadvantages of a placebo-controlled trial for answering this preterm birth 
prevention question: 1) knowledge of vaginal colonisation with Candida may change 
participants’ behaviour such that they seek active therapy (clotrimazole is available over the 
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counter); 2) a vaginally administered placebo may be biologically active as it would have to 
contain an alcohol preservative that could have an independent affect on vaginal flora.[34] 
 
This review is limited by the lack of trials, and that one of the included trials is a small pilot 
study. Previous research has mostly focussed on the question of best treatment for eradicating 
Candida colonisation in pregnant women with symptomatic candidiasis. The availability of 
only two trials precludes the opportunity to explore issues like heterogeneity and any impact 
of reporting biases in sensitivity and subgroup analyses.  Only one outcome (spontaneous 
preterm birth) was available from both studies, and future trials should consider other 
potential pregnancy outcomes and treatment side effects.[46] Although we identified 11 
treatment trials of symptomatic candidiasis in pregnancy, all were published before 1985, 
only one compared treatment to placebo and none reported pregnancy outcomes, only the rate 
of Candida eradication.[24, 35, 36, 47-54] Furthermore, the seven studies that reported 
gestational age at recruitment all included women who were too advanced in pregnancy to 
have an impact on preterm birth.[24, 35, 36, 48, 50, 52, 54] 
 
In contrast, the rationale of the two included trials is that early treatment of vaginal infections 
is necessary for effective prevention of infection-related preterm birth, as early pregnancy is 
the period of greatest risk for the establishment of inflammatory responses to low virulence 
organisms that increase the risk of preterm birth.[6-9]  Treatment later in pregnancy may 
have limited effect in preventing preterm parturition if the inflammatory responses are not 
fully reversible.[4] Importantly, treatment does not necessarily eradicate Candida in all 
women nor prevent recolonisation.  Post-treatment ‘Candida eradication rates’ (assessed at 3-
6 weeks) for symptomatic candidiasis in pregnancy range from 69% to 100% (5 trials, median 
88%)[55] and for asymptomatic candidiasis was 73% (assessed at 4-5 weeks) in the Kiss 
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trial[28] and 52% (assessed at 10 weeks) in the Roberts trial.[34] However it is not clear 
whether post-treatment colonisation represents persistent colonisation or recolonisation. 
 
It is somewhat surprising that only two trials could contribute to this review, given the 
interest in infection as a risk factor for preterm birth.  Perhaps as Candida is considered a 
vaginal commensal organism,[13] the role of candidiasis in preterm birth has not been 
pursued with the same attention as bacterial vaginosis and other vaginal organisms.[11, 56-
59] 
 
Conclusion 
The findings of this review support the hypothesis that screening for and treating 
asymptomatic candidiasis in early pregnancy may reduce spontaneous preterm birth rates. If a 
simple, inexpensive intervention is demonstrated to reduce spontaneous preterm birth, this 
would change current maternity care internationally. A significant reduction in preterm birth 
would not only reduce perinatal mortality and morbidity but have major resource 
implications, such as reduced need for neonatal intensive care and childhood hospitalisations. 
This systematic review suggests that a trial with sufficient power to answer the clinical 
question ‘does treatment of asymptomatic candidiasis in early pregnancy prevent preterm 
birth’ is warranted. 
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Table 1: Characteristics of randomised controlled trials assessing treatment of vaginal candidiasis to prevent preterm birth 
 
Study Study period & 
location 
Study population Study size 
(Candidiasis) 
Intervention Comparison Available outcomes among 
women with candidiasis 
Kiss et al 2001-2002 
25 non-hospital 
based obstetricians 
Vienna, Austria 
Pregnant women 
15
0
-19
6
 weeks 
gestation 
No symptoms  of 
vaginal infection, 
bleeding or 
contractions 
 
586 
294 randomised to 
treatment 
292 randomised to 
usual care 
Vaginal 
clotrimazole 
0.1g for six days 
 
Usual care   
(vaginal  culture result not 
revealed, no treatment) 
Spontaneous preterm birth 
Roberts et al 2008-2009 
Single tertiary 
obstetric hospital, 
Sydney, Australia 
Pregnant women 
12
0
-19
6
 weeks 
gestation 
No symptoms  
vaginal infection 
99 
50 randomised to 
treatment 
49 randomised to 
usual care 
Vaginal 
clotrimazole 
0.1g for six days 
Usual care   
(vaginal  culture result not 
revealed, no treatment) 
Spontaneous preterm birth; any 
preterm birth; pregnancy 
complications; mode of 
delivery, birthweight. 
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Figure legends 
Figure 1: Summary of evidence search and selection 
 
Figure 2: Meta-analysis: relative risk of spontaneous preterm birth among women with 
asymptomatic candidiasis: clotrimazole versus usual care (no screening and no treatment for 
asymptomatic candidiasis) 
 
